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This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).SUMMARYReprogramming of somatic cells produces induced pluripotent stem cells (iPSCs) that are invaluable resources for biomedical research.
Here, we extended the previous transcriptome studies by performing RNA-seq on cells defined by a combination of multiple cellular sur-
face markers. We found that transcriptome changes during early reprogramming occur independently from the opening of closed chro-
matin by OCT4, SOX2, KLF4, and MYC (OSKM). Furthermore, our data identify multiple spliced forms of genes uniquely expressed at
each progressive stage of reprogramming. In particular, we found a pluripotency-specific spliced form ofCCNE1 that is specific to human
and significantly enhances reprogramming. In addition, single nucleotide polymorphism (SNP) expression analysis reveals that mono-
allelic gene expression is induced in the intermediate stages of reprogramming,while biallelic expression is recovered upon completion of
reprogramming. Our transcriptome data provide unique opportunities in understanding human iPSC reprogramming.INTRODUCTION
Induced pluripotent stem cells (iPSCs) have similar proper-
ties as embryonic stem cells (ESCs), such as self-renewal
and differentiation capacity (Park et al., 2008c; Takahashi
and Yamanaka, 2006). Reprogramming technique offers
tremendous potential for diseasemodeling, cell-based ther-
apy, and drug screening (Park et al., 2008a). Although the
reprogramming process is quite robust and applicable to
various types of adult differentiated cells, only a small frac-
tion of donor cells reaches a fully pluripotent state, while
the majority are refractory to reprogramming. Imperfect
reprograming may carry somatic memory and may
contribute to cancer development (Ohnishi et al., 2014).
Therefore, efficient selection and generation of bona fide
iPSCs are essential for safe uses in regenerative medicine.
Serial live cell imaging is one of the tools to distinguish
bona fide human iPSCs (hiPSCs) from partially reprog-
rammed cells. Previously, we identified three distinct
types of expandable hESC-like colonies during reprogram-
ming via expression patterns of virus-derived GFP,
fibroblast marker CD13 (ANPEP), and two pluripotent
markers SSEA4 and TRA160 (Chan et al., 2009). Type I cells
are defined by continuous expression reprogramming
genes (CD13GFP+SSEA4TRA160). Type II cells express
pluripotency marker SSEA4 and continue expressing re-
programming factors (CD13GFP+SSEA4+TRA160). TypeStem CIII cells show expression of TRA160 as well as SSEA4
(CD13GFPSSEA4+TRA160+). Among these types of col-
onies, only type III has similar molecular phenotypes
with hESCs and become bona fide hiPSCs. Type I and
type II cells are partially reprogrammed cells and display
negative nuclear NANOG staining, low expression of
several pluripotent genes (e.g., DNMT3B and REX1), and
a distinct epigenetic state from type III cells and hESCs.
Type I cells remain in their incomplete reprogramed state,
while a small population of type II cells may still convert
to type III cells and complete hiPSC reprogramming.
Reprogramming pathways have been extensively stud-
ied. Mesenchymal-to-epithelial transition (MET) occurs in
the initial phase of reprogramming and is synergistically
activated by OCT4, SOX2, KLF4, and MYC (OSKM) and
BMP signaling, but is blocked by the transforming growth
factor b (TGF-b) pathway (Li et al., 2010; Samavarchi-Teh-
rani et al., 2010). Despite the active function of BMP in
the initial reprogramming, BMP proteins prevent the tran-
sition of pre-miPSCs to fully reprogrammed miPSCs by
maintaining H3K9 methylation (Chen et al., 2013). In
contrast, ACTIVIN/NODAL signaling pathway, which is a
branch of TGF-b signaling, is essential for mESC self-
renewal (Ogawa et al., 2007). WNT ligands and a down-
stream component of WNT signaling pathway, b-catenin,
are required to prevent differentiation and maintain self-
renewal in mESCs (Lyashenko et al., 2011). Whereas theell Reports j Vol. 4 j 1125–1139 j June 9, 2015 j ª2015 The Authors 1125
transcriptional repressor TCF3 inhibits mESC self-renewal,
an interaction with b-catenin followed byWNT3A stimula-
tion activates the expression of self-renewal genes by block-
ing the TCF3 repressive activity (Yi et al., 2011). A recent
study further defined the role of WNT, revealing that this
pathway is a negative regulator in the early stages, but
switches to a positive regulator in the late stage of mouse
reprogramming (Ho et al., 2013).
Transcription profiling during reprogramming has pro-
vided critical insights into understanding reprogramming.
Microarray-based transcriptome analysis in miPSCs and
partially reprogrammed murine cell populations sorted by
a fibroblast marker (THY1) and two pluripotent markers
(SSEA1 and Oct4-GFP) revealed that the reprogramming
process is composed of two main transcriptional waves
(Polo et al., 2012). The first wave is driven by Myc and
Klf4 and characterized by the loss of fibroblast identity
and a gain in cell proliferation. The second wave is
controlled by Oct4, Sox2, and Klf4 and is associated with
changes in DNA methylation that facilitate stable pluripo-
tency. A microarray and single-cell qPCR study of cell pop-
ulations sorted by virus-driven EGFP and TRA160 in hiPSC
reprogramming, showed that TRA160+ cell populations at
late time points (approximately day 28) exhibit more
similar gene expression patterns to hESCs and less hetero-
geneous than those at early time points (approximately
day 11) (Tanabe et al., 2013). However, most of the nascent
TRA160+ cells fail to complete reprogramming. These
recent reports indicate that transcriptional and signaling
regulatory networks are different among intermediate
steps.
Here, we set out to investigate the progressive steps of
hiPSC reprogramming by Phi29 DNA polymerase-based
mRNA-sequencing (Phi29-mRNA amplification [PMA]
RNA-seq) that enables us to monitor transcriptomes in
scarce intermediate cell populations (Pan et al., 2013). We
identified unique pluripotency-specified spliced transcripts
and determined a surprising function of a spliced form of
CCNE (pCCNE1) in improving the reprogramming effi-
ciency. We also found that the actively reprogramming in-
termediate stage cells acquire a unique ASE pattern, which
is erased when reprogramming is completed. Overall, our
data analyses allowed us to further dissect the mechanism
of hiPSC reprogramming.RESULTS
Strategy of Transcriptome Profiling from Partially
Reprogrammed Cell States
In order to facilitate isolating cells undergoing reprogram-
ming, we initiated reprogramming in human primary
fibroblasts with pMSCV-IRES-GFP-based retroviral vectors1126 Stem Cell Reports j Vol. 4 j 1125–1139 j June 9, 2015 j ª2015 The Autexpressing OSKM (Park et al., 2008b). Cells were harvested
at day 3 andweeks 1, 2, 3 and 4 after the viral infection (Fig-
ure S1A). The intermediate reprogramed cells from weeks 1
to 4 were further separated by fluorescence-activated cell
sorting (FACS) using antibodies for CD13, SSEA4, and
TRA160 or GFP expression. At week 1, the majority of cells
express virus-derived GFP (Figure S1B), and around 96.9%
of those GFP+ cells expressed CD13. Double-positive cells
(GFP+CD13+) alsomade up themajority of week 2 cell pop-
ulations (31.3%), but the ratio of GFP+CD13 cells was
greatly increased (20.9%). We observed that 2.7%
(GFP+CD13 SSEA4+ and GFPCD13 SSEA4+) of cells at
week 2 showed SSEA4 expression with loss of CD13 expres-
sion. At weeks 3 and 4, the major cell population consisted
of GFP+SSEA4TRA160 cells (70.0% and 17.5%, respec-
tively), but around 4%–6% of cells displayed expression
of two pluripotent markers without GFP expression
(GFPSSEA4+TRA160+). At week 4, colonies showing
hESC-like morphology with CD13GFPSSEA4+TRA160+
cell surface markers were picked for expansion and here
on referred to as established iPSCs (grouped together with
ESCs in subsequent analyses). PMA RNA-seq was per-
formed in 18 intermediate cell populations, three replicates
of parental fibroblasts, fibroblasts at day 3 post-OSKM in-
duction, as well as ESCs and two types of established iPSCs
(Pan et al., 2013).
Initial Gene Regulation by OSKM Overexpression in
hiPSC Reprogramming
To examine genes immediately regulated by OSKM induc-
tion, we compared the transcriptome profile in cells
3 days post-ectopic OSKM overexpression with that of
parental fibroblast cells (Figure 1A). Gene Ontology (GO)
analysis showed that upregulated genes at day 3 are related
to ‘‘type I interferon signaling pathway’’ and ‘‘histone
modification’’ (Figure 1B). These genes include EHMT1,
EZH2 (Onder et al., 2012), HMGA1 (Shah et al., 2012),
MED12 (Chia et al., 2010), RARG (Wang et al., 2011), and
TAF11 (Maston et al., 2012), which are highly expressed
in hESCs and are required for self-renewal, maintenance
of pluripotency, or hiPSC reprogramming. Downregulated
genes are involved with ‘‘cell development’’ and ‘‘TGF-b
signaling pathway.’’ Inhibition of the TGF-b signaling
pathway has been characterized and previously shown to
enhance iPSC reprogramming (Ichida et al., 2009). These
initial responses to OSKM are also detected by reprogram-
mingwith electroporation of episomal vectors (Figure S1C).
Since the type I interferon pathway is also triggered by the
empty vector with infection or electroporation, the induc-
tion of this pathway seems to be a general cellular response
to foreign viral DNA and not OSKM per se, as both the
pMSCV construct and episomal plasmids have been assem-
bled with viral elements (retrovirus and Epstein-Barr virus,hors
Figure 1. Initial Gene Regulation by OSKM
(A) Comparison of gene expression in OSKM-induced cells between days 0 and 3. Differentially expressed genes (>4-fold) related to
‘‘histone modification (GO: 0016570)’’ or ‘‘transcription factor binding (GO: 0008134)’’ are shown by red dots.
(B) GO analysis of upregulated and downregulated genes at day3. Dashed line represents 0.05 FDR.
(C and D) Comparison of (C) histone modification and (D) OSKM binding level in fibroblast stage with gene expression changes at day3.
The x axis represents the rank of genes sorted by increasing order of log2(day 3/day 0) values. The y axis represents log2(ChIP/input).
Colors represent log10(count).
See also Figure S1.respectively). Thus, our data support that the major role of
OSKM in the early phase of reprogramming is the activa-
tion of reprogramming-related histone remodelers and
transcription factors and the suppression of signaling path-Stem Cways interfering with iPSC reprogramming. This early plas-
ticity, also observed in our 3-day RNA-Seq data, can be
utilized to direct differentiation to any lineage of choice
(Efe et al., 2011).ell Reports j Vol. 4 j 1125–1139 j June 9, 2015 j ª2015 The Authors 1127
(legend on next page)
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We next asked whether chromatin signatures in the
parental fibroblasts and the initial binding of OSKM at pro-
moters determine the genes regulated in the initial phase of
reprogramming. To this end, the upregulated and downre-
gulated genes at day 3were compared with public ChIP-seq
studies for histone modifications (Bernstein et al., 2010)
and OSKM (Soufi et al., 2012) in fibroblast cells. We did
not observe a distinct correlation of the histone modifica-
tion level and initial OSKM binding between upregulated
and downregulated genes at day 3. However, both upregu-
lated and downregulated genes at day 3 showed signifi-
cantly higher open chromatin marks H3K4me3 and
H3K27ac and lower closed chromatin mark H3K27me3
than non-regulated genes (Figure 1C). In addition, OCT4,
KLF4, and MYC, but not SOX2, are significantly enriched
in both initially regulated promoters (Figure 1D), indi-
cating that genes within pre-existing open chromatin re-
gions are initially regulated by OKM, which act as both
activators and repressors.
Transcriptome Analysis Revealed Three
Representative Intermediate States during hiPSC
Reprogramming
Consistent with our previous classification (Chan et al.,
2009), principle component analysis (PCA) segregates the
partially reprogrammed cell populations into three distinct
stages (types I, II, and III) as well as fibroblast-like and ESC/
iPSC stage (Figure 2A). Parental fibroblasts, day 3 reprog-
rammed cells, and CD13+GFP+ cells at weeks 1 and 2 were
grouped into the fibroblast-like stage. Typical type I cells,
grouped as type I stage, represented by CD13GFP+SSEA4
at weeks 1, 2, and 4, are distinguishable from the fibroblast-
like stage, and close to CD13+GFP+SSEA4+, CD13GFP+
SSEA4+, or CD13GFPSSEA4+ at week 2, suggesting that
repression of the fibroblast phenotype (transition from
CD13+ to CD13) or induction of a pluripotent phenotype
(SSEA4 to SSEA4+) represents the exit from the fibroblast-
like stage. Type I cells are the closest to the fibroblast-like
stage and neighbor type II and III stages of cells, suggesting
that the fibroblast-to-type I transition is the first barrier in
the path to iPSCs. Type II stage represents GFP+SSEA4+
TRA160 cell populations and resides closer to type I stage
than type III. Type II is the most distant stage from fibro-
blasts and ESC/iPSCs. Type III stage is composed of
GFPSSEA4+TRA160+ cells and shows the most similar
transcriptional patterns with ESCs and iPSCs. Despite theFigure 2. Characterization of Intermediate Stages in hiPSC Repro
(A) PCA classification of the human intermediate states.
(B and C) GSEA of stem cell functions (B) between distinct human i
induced or repressed in the transition between two stages (log10(F
(D and E) GSEA of ECC and ESC-specific genes in (D) human and (E) m
See also Figure S1.
Stem Crepression of CD13 from the fibroblast-like stage, the
expression levels of several other fibroblast markers, such
as COL1A1 and COL1A2, are higher in types I and II than
ESC/iPSCs. Meanwhile, the expression of these genes in
type III cells is as low as that of ESC/iPSCs, indicating
that the fibroblast signature still exists in types I and II stage
(Figure S1D). GFPSSEA4+TRA160 cell populations at
weeks 3 and 4 are located between type II and type III stages
and are hypothesized to be in the course of transition from
types II to III. Between type III and ESC/iPSCs stage, the
expression levels of OSKM and the other pluripotency reg-
ulators (e.g., NANOG) were not significantly different
(Table S1). Around 900 genes show significantly higher
expression in ESC/iPSC stage compared with type III (Fig-
ure S1E) and are overrepresented as ‘‘chromatin modifica-
tions’’ and ‘‘transcription cofactor activity’’ (Figure S1F).
Next, our transcriptome data were compared with gene
signatures of unsorted and sorted populations (GFP+
TRA160, or TRA160+) from the published work (Tanabe
et al., 2013) by gene set enrichment analysis (GSEA) (Table
S2A). All of these signatures are significantly induced in the
transition from fibroblast-like to type I stage and also are
upregulated in later stages (Figure S1G). Gene signatures
at mature stages (TRA160+ cells and iPSCs) are significantly
enriched in the I-to-III and II-to-III transitions (false
discover rate [FDR] < 0.001), but not in the I-to-II, support-
ing our observations that type III is closer to ESC/iPSC. In
the I-to-II transition, only the gene signature at middle
time point (day 11) is significantly enriched (FDR <
0.001). The iPSC signature is also induced in III-to-ESC/
iPSC transition (FDR = 0.001), suggesting that while close
to ESC/iPSC, type III cells have not fully completed
reprogramming.
Population-based transcriptome analysis provides amore
robust quantification of gene expression and has relatively
low technical noise and high reproducibility (Marinov
et al., 2014). Although it is very useful to flesh out the char-
acteristics of the whole population, we cannot gauge the
biological variation between the cells comprising that pop-
ulation. In order to investigate the heterogeneity of the
intermediates, we compared our data with single-cell data-
sets obtained from partially reprogrammed cells (Chung
et al., 2014). Consistently, the majority of double-positive
cells (SSEA4+TRA160+) and none of SSEA4+TRA160 and
GFP+ cells were classified into type III group (Figures S1H
and S1I). While more than 75% of type II cells aregramming
ntermediate stages and (C) mouse intermediate stages. Gene sets
DR)) are shown by red and blue color, respectively.
ouse.
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SSEA4+TRA160, more than 60% of type I cells are GFP+,
indicating that the sorted-cell populations display hetero-
geneity, but mainly occupy specific intermediate stages.
Overall, our transcriptome data are highly reliable and
allow us to understand gene regulation changes during
hiPSC reprogramming.
Primed andNaive-State Signatures Are Induced during
iPSC Reprogramming
Despite many previous efforts to induce a naive-state in
hESCs and hiPSCs (Takashima et al., 2014; Theunissen
et al., 2014), it is still unclear whether or when OSKM
induction is responsible for naive- and primed-state prop-
erties. To address the ground state in intermediate reprog-
ramming stages, we analyzed the enrichment of genes
specifically expressed in naive or primed ESCs (Figure 2B;
Table S2B). GSEA revealed that primed-state signatures
were significantly induced in fibroblast-to-I (FDR = 0.001)
and type III-to-ESC/iPSC transition (FDR = 0.001). In
contrast, naive-state signatures were significantly enriched
in I-to-III (FDR = 0.001) and II-to-III transitions (FDR =
0.017). Significant repression of the primed-state was
observed in I-to-II (FDR = 0.001) and I-to-III transitions
(FDR = 0.001). These results indicate that type I and ESC/
iPSC are biased to the primed state, whereas type III is to
naive state. Type II is represented by a large depletion of
primed-state signatures and no induction of naive-state sig-
natures. Unlike dynamic changes of naive and primed sig-
natures in human, murine iPSC reprogramming showed
across-the-board increase of naive-specific (FDR < 0.001)
and decrease of primed-specific genes (FDR < 0.017) in all
intermediate stages (Figure 2C) (Polo et al., 2012).
We further addressed the expression changes in genes
related to stem cell functions (Figure 2B). Genes related to
stem cell maintenance and development and telomere
maintenance are significantly induced in I-to-III and II-
to-III transitions (FDR < 0.005). These gene sets are sig-
nificantly depleted in I-to-II transition (FDR < 0.002),
indicating that stem cell properties are gained with naive-
state induction in type III. Gene sets involved in fibroblast
proliferation are significantly suppressed in I-to-II and I-to-
III transitions, confirming that type I stage still has fibro-
blast features. We observed a significant reduction of
EMT-upregulated genes in MEF-to-ThyI+ transition in
mouse (FDR = 0.001) (Figure 2C). On the other hand, we
found a significant induction of epithelium developmental
genes in fibroblast-to-I transition (FDR = 0.005) and a
reduction of EMT-upregulated genes in I-to-II and I-to-III
transitions (FDR = 0.003 and 0.001, respectively) in hiPSC
reprogramming. This suggests that MET is required in
both early and intermediate phases and promotes the exit
of human reprogramed cells from the type I stage. Consis-
tent with our previous finding that human female fibro-1130 Stem Cell Reports j Vol. 4 j 1125–1139 j June 9, 2015 j ª2015 The Autblasts reactivate their inactive X chromosome during
hiPSC reprogramming (Kim et al., 2014b), X-chromosome
inactivation (XCI)-related genes are significantly repressed
in fibroblast-to-I (FDR = 0.047) and are induced in III-to-
ESC/iPSC stage (FDR = 0.042).
Cells in Type I Stage Present the Tumorigenic Potential
Since somatic reprogramming is induced bymultiple onco-
genic factors, the tumorigenic potential of iPSCs is a major
concern for using iPSCs in cell therapy. To examine the
tumorigenicity of each intermediate stage of reprogram-
ming, we performed GSEA of cancer-related genes (Fig-
ure 2D). Since many oncogenes overlap with pluripotent
genes, differentially expressed genes between ESCs and em-
bryonic carcinoma cells (ECCs), amalignant counterpart of
ESCs, were used as a cancer-related gene set (Table S2D)
(Chang et al., 2010; Sperger et al., 2003). In hiPSC reprog-
ramming, we observed that ECC-specific genes are signifi-
cantly enriched in fibroblast-to-I transition (Figure 2D;
FDR = 0.019). Interestingly, ECC-specific genes are signifi-
cantly depleted in I-to-II, I-to-III, and II-to-III transitions
(FDR = 0.001, 0.007, and 0.001, respectively). Additionally,
a significant induction of ESC-specific genes was observed
in I-to-III and II-to-III transitions (FDR = 0.001 and 0.001,
respectively), indicating that type I is more tumorigenic
than the other intermediate stages. This is consistent
with our previous report demonstrating the formation of
poorly differentiated teratomas from type I cells when in-
jected into immunodeficient mice (Chan et al., 2009). In
mouse, ECC-specific genes are significantly induced at
Oct4-GFP+ stage (FDR = 0.001), but are reduced at mature
iPSCs (FDR = 0.001) (Figure 2E). Our results show that
tumorigenic potential was induced at the early and late
stage of iPSC reprogramming in human and mouse,
respectively.
Unique Alternative Splicing in Reprogramming
Alternative splicing (AS) is a key event to generate multiple
isoforms and functional diversity in proteins. ESC/iPSC- or
type III-specific isoforms are hypothesized to modulate the
regulation of pluripotency and self-renewal. To identify
stage-specific AS events, we compared spliced read align-
ments among different reprogramming stages (Figure S2A).
A total of 636,803 junctions were aligned by our RNA-seq
libraries, and about 24.6% of them were matched with
splicing sites of RefSeq genes; 47.7% of them were not
matched with RefSeq splicing sites, but were observed
within RefSeq gene bodies. Spliced junctions within RefSeq
genes were further filtered by (1) stage specificity score, (2)
gene expression level, and (3) normalized counts of reads
spanning the junction (see Experimental Procedures).
Finally, a total of 2,342 (0.367%) splice junctions in 774
genes were identified as stage-specific AS candidateshors
(Figure 3A). These candidates include spliced junctions in
known differentiated cell- or ESC-specific isoforms of
FOXP1 and MBD2 (Gabut et al., 2011; Lu et al., 2014) (Fig-
ures S2B and S2C).
In this study, we focused on the function of a previously
uncharacterized variant from theCCNE1 gene. This variant
excludes a highly conserved exon 9 of CCNE1 (Fig-
ure S3A), leading to the modification of Cyclin C-terminal
(Cyclin_C) domain (Figure 3B). RT-PCR assay confirmed
that the exclusion of exon 9 is observed only in pluripo-
tent-cell stages (type III and ESC/iPSC) (pCCNE1, pluripo-
tent CCNE1) (Figure 3C). In contrast, the known isoform
of CCNE1 (NM_001238) is ubiquitously expressed from fi-
broblasts to ESC/iPSC stage (uCCNE1, ubiquitous CCNE1).
Since pCCNE1 is also detectable in reprogramming with
somatic cell nuclear transfer, Sendai virus (Figure S3B),
episomal vectors (Figure S3C) and polycistronic OSKM
lentivirus (Figures S3D and S3E), its induction does not
depend on reprogrammingmethods.Whereas ESC-specific
isoforms of Foxp1 and Mbd2 were also observed in mESCs
(Figures S2B and S2C), exon 9 skipping ofCcne1was not de-
tected in mouse embryonic fibroblasts (MEFs), epiblast
stem cells (EpiSCs) and ESCs (Figures 3D and 3E), indi-
cating that pCCNE1 is a human-specific transcript variant.
Despite the high levels of uCCNE1 and pCCNE1 in type
III stage and ESCs/iPSCs (Figures 3D and S3B–S3E), neither
isoform is considerably expressed in fibroblasts after indi-
vidual or combinatorial OSKM overexpression (Figures
S3F and S3G). However, pCCNE1 expression is significantly
increased by uCCNE1 overexpression (p = 2.21e-4), whereas
pCCNE1 does not affect uCCNE1 transcription (p = 0.077).
These results suggest that the stem cell-specific splicing of
CCNE1 is not an initial target of OSKM; instead, it is most
likely controlled by a higher amount of uCCNE1 and the
transcriptional and signaling networks of pluripotency es-
tablished in mature hiPSCs (Figure S3H).
Given the specificity of pCCNE1 expression in the plurip-
otent stage, we next asked about the functional differences
between pCCNE1 and uCCNE1. Consistent with our
knowledge that CCNE1 is involved in the cell cycle (Honda
et al., 2005), overexpression of uCCNE1 significantly accel-
erates cell proliferation (p = 0.033 by one-side t test;
Figure 3F). In contrast, pCCNE1 displays little effect on
cell-cycle progression (p = 0.058). Furthermore, pCCNE1
cannot enhance cell proliferation even after OSKM induc-
tion (p = 0.312; Figure 3G), indicating that pCCNE1 loses
its (if any) functional role in the cell-cycle progression dur-
ing reprogramming. Interestingly, overexpression of
pCCNE1, but not uCCNE1, with OSKM significantly
increased the efficiency of hiPSC reprogramming by
4-foldmore thanOSKM alone (p = 0.022) or empty vector +
OSKM (p = 0.022) (Figure 3H), as quantified by alkaline
phosphatase (AP) staining. We validated our reprogram-Stem Cming data by double staining iPSCs with pluripotency
markers SSEA4 and TRA160 (Figure S3I). Taken together,
our results indicate that pCCNE1 is a newly identified
pluripotent spliced form utilized by somatic cells to acquire
pluripotency in a cell cycle-independent manner.
Monoallelic Gene Expression Is Uniquely Induced in
Reprogramming
Allele-specific expression (ASE) is one of the gene regula-
tory systems that increase gene variations in a cell. A major
change in ASE is known to occur during the pre-implanta-
tion development following maternal mRNA loss and
paternal genome activation. Zygotic gene activation is
induced at four- to eight-cell transition in humans and at
one- to two-cell transition in mice (Xue et al., 2013),
whereas in the blastocyst, the majority of genes are ex-
pressed biallelically. ESCs and differentiated cells display
around 65%–80% of biallelic gene expression (Eckersley-
Maslin et al., 2014). Despitemuch interest in its regulation,
the ASE change during hiPSC reprogramming has been
poorly understood due to the absence of advanced molec-
ular tools. Thus, we measured the heterozygous single
nucleotide polymorphism (SNP) expressions in each cell
population isolated during reprogramming and calculated
ASE ratios (reference:alternative allele expression ratios)
for 105 SNPs observed within genes expressed in parental
fibroblasts, intermediate stages, and established iPSCs; 68
of 105 SNPs were known SNPs registered in dbSNP Build
132 (Figure 4A). ASE ratios showing symmetric distribution
with the highest peak at 0.5 were observed in parental fi-
broblasts, cell populations expressing fibroblast marker
CD13 (GFP+CD13+), and iPSCs (Figure 4B), consistent
with our previous report (Lee et al., 2009). This indicates
that most genes are expressed from both alleles, or cells ex-
pressing either allele are equally mixed in these popula-
tions. On the other hand, in types I, II, and III-stage cell
populations, ASE ratios in several SNPs were increased
and decreased closer to 1 or 0, respectively, indicating
that either allele is preferentially expressed during hiPSC
reprogramming. The bias level of allelic preference is signif-
icantly higher in types I, II, and III than the fibroblast stage
(Figure 4C; p = 4.14e-3, 4.29e-2, and 6.50e-4, respectively).
This ASE bias was also observed in polycistronic vector-
based reprogramming, indicating that the occurrence of
ASE is not a corollary to individually expressed transgenes
(Figure S3J).
To validate ASE during iPSC reprogramming, we selected
two SNPs in the RPN and P4HB genes and analyzed the SNP
expression by Sanger sequencing (Figure 4D). These genes
were expressed from both alleles (C and T) in parental
D551 fibroblast, fibroblast-stage cell population, and
iPSCs, while either allele (C or T) was predominantly or







Figure 3. Alternative Spliced Forms of Genes Specific to Each Stage of Reprogramming
(A) Differential expression patterns of splice junctions. Colors represent the normalized read count mapped to each splice junction.
(B) Schematic representation of functional domains of splicing isoforms of CCNE1. Gray, blue, and red rectangles represent open reading
frame, CYCLIN, and Cyclin_C domain, respectively. Pink rectangles represent the truncated Cyclin_C domain resulting from exon 9 skipping.
(C) RT-PCR assay using primers targeting exons 8 and 10. (Left) is derived from parental fibroblasts and H9 ESCs. (Right) is derived from
sorted intermediate populations: Fib-like (w1 CD13+ GFP+), type I (w2 CD13+ GFP+ SSEA4+), II (w4 GFP+ SSEA4+ TRA160+), III (w4 GFP
SSEA4+ TRA160+), and iPSC.
(D and E) Exon 9 skipping of CCNE1 in (D) human and (E) mouse somatic and pluripotent stem cells.
(legend continued on next page)
1132 Stem Cell Reports j Vol. 4 j 1125–1139 j June 9, 2015 j ª2015 The Authors
Figure 4. ASE Occurs in Intermediate Stages of hiPSC Reprogramming
(A) Overlap of 105 detected SNPs with dbSNP.
(B) Histograms of ASE ratios in six representative cell populations. Value below histogram represents ASE bias.
(C) Comparison of average ASE bias among different intermediate stages (*p < 0.05 by one-sided t test). The number in parentheses
denotes the number of populations in each class.
(D) Confirmation of ASE patterns of RPN and P4HB by Sanger sequencing.
See also Figure S3.indicate that ASE occurs in the intermediate stages and that
biallelic expression is restored when cells complete iPSC
reprogramming.
Biphasic Change of Signaling Pathways
To gain insight into themechanisms of signaling pathways
in iPSC reprogramming, we analyzed their enrichment at(F and G) Effect of CCNE1 variants on cell growth rate. Fold change of ce
with OSKM induction (*p < 0.05 by one-side t test, three biological r
(H) Positive regulation of hiPSC reprogramming by pCCNE1 overexpres
induced by overexpression of empty vector, uCCNE1, or pCCNE1 with r
represent SD.
See also Figures S2 and S3.
Stem Ceach intermediate stage (Figure 5A; Table S2C). Type I-to-
II transition was well represented by the reduction of
most signaling pathways, while type II-to-III transition
was characterized by the induction of NOTCH and WNT
(FDR < 0.042; Figure 5B). Signaling pathways normally
reduced or blocked in iPSC reprogramming (p53, neurotro-
phin, and MAPK) were indeed significantly repressed inll count at day 11 to that at day 0 was calculated (F) without and (G)
eplicates). Error bars represent SD.
sion. (Right) represents representative AP+ colonies in 12-well plate
eprogramming factors OSKM (three biological replicates). Error bars
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Figure 5. Biphasic Change of Signaling
Pathways during hiPSC Reprogramming
(A and B) GSEA of signaling pathways (A)
between distinct human intermediate
stages and (B) between distinct mouse in-
termediate stages.
(C and D) The count of significantly upre-
gulated (red) or downregulated (blue)
pathways in (C) human and (D) mouse iPSC
reprogramming.
See also Figure S4.I-to-II, I-to-III, and II-to-III transitions (FDR < 0.009) (Hong
et al., 2009; Ishizuka et al., 2014; Levenberg et al., 2005). No
significant induction or repression of any signaling path-
ways was observed in fibroblast-to-I and III-to-ESC/iPSC
transition.
NOTCH signaling is one of the pathways that display a
biphasic change. By addingNOTCH inhibitor DAPTor acti-
vator DLL4 ligand at specific periods of reprogramming
(Figure S4A), we found that NOTCH inhibition at an early
time point and activation at a late time point is more effi-
cient than vice versa in enhancing reprogramming (Figures
S4B and S4C). These data suggest that biphasic change
of signaling pathway is an important consideration to
improve the efficiency of iPSC reprogramming.
Conversely, we found no significant induction inmost of
signaling pathways between intermediate cells during mu-
rine iPSC reprogramming (Figures 5C and 5D). Only the
P53 signaling pathway was significantly upregulated in
Oct4-GFP+-to-iPSC transition (FDR = 0.001). These results1134 Stem Cell Reports j Vol. 4 j 1125–1139 j June 9, 2015 j ª2015 The Autsuggest distinct signaling mechanisms during iPSC reprog-
ramming between human andmouse or, alternatively, that
hiPSC reprogramming is more sensitive to signaling
pathways.
Type III and ESC/iPSC Signatures Are Co-regulated by
Multiple Pluripotent Transcription Factors
Developmental genes have high factor loadings (FLs),
while genes associated with the cell cycle and stem cell
development have low FLs in principle component (PC) 2
and 3 (Figure S5A). Using FLs in PC1-3, we classified genes
into three groups that are highly expressed in fibroblast
type I (957 genes), type II (123 genes), and III-ESC/iPSC
(511 genes) (Figure 6A; Table S3). The fibroblast type I
group includes many fibroblast-specific markers such as
CD13, COL1A1, COL1A2, and S100A4. In contrast, type
III-ESC/iPSC group contains known pluripotency genes
such as LIN28A, NANOG, PRDM14, ZFP42 (REX1), and
DNMT3B. The type II group includes genes that bothhors
Figure 6. Transcriptional Regulation of Type III and ESC/iPSC Signatures by Multiple Pluripotent Factors
(A) Genes preferentially expressed in fibroblasts and type I, type II, and type III and ESC/iPSC. FLs in PC1–3 of each gene are plotted.
(B) Ratios of NANOG, PRDM14, and LIN28A target genes in fibroblast and type I, type II, and type III and ESC/iPSC gene sets.
(C) Endogenous OSKM expression patterns during hiPSC reprogramming. Relative expression to average was shown by color range blue (low
expression) to yellow (high expression).
(D) NANOG, PRDM14, and LIN28A binding patterns in OSKM loci.
(E) Model of reprogramming milestones.
See also Figure S5.
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promote (OGT and PAF1) and block pluripotency and self-
renewal (LEFTY2) (Ding et al., 2009; Jang et al., 2012; Kim
et al., 2014a).
To understand the regulatory mechanism of type III and
iPSC gene signatures, we analyzed genes targeted by three
main pluripotency regulatory factors (NANOG, PRDM14,
and LIN28A) enriched in type III/ESC/iPSCs by using pub-
licly available ChIP-seq and CLIP-seq datasets (Chia et al.,
2010; Kunarso et al., 2010; Wilbert et al., 2012). Whereas
NANOG binds more than 15,000 gene loci, PRDM14 and
LIN28A targets comprise around 5,000 genes (Figure S5B).
In addition, more than 95% of LIN28A and PRDM14 tar-
gets were co-targeted by NANOG. NANOG targets were
significantly enriched in the fibroblast type I (p = 1.20e-
12 by hypergeometric test) and type III-ESC/iPSC groups
(p = 6.26e-3), but not in type II (p = 0.999) (Figures 6B
and S5C). However, unique targets of NANOG are only
significantly enriched in the fibroblast type I group (p =
2.86e-5), but not in type II (p = 0.983) and type III-ESC/
iPSC groups (p = 0.871), suggesting that the gene regulation
of type III-ESC/iPSC group is mediated by co-regulation of
NANOG and the other pluripotent factors.
We found that endogenousOCT4 and SOX2 RNA expres-
sions are only induced in type III and ESC/iPSCs (Figure 6C;
Table S4). Since endogenous Oct4, Sox2, and Klf4 are
induced in iPSCs and ESCs (Figure S5D), human andmouse
employ distinct regulatory mechanisms to establish iPSCs.
Co-targets of OCT4 and SOX2 were significantly enriched
in type III-ESC/iPSC group (Figure S5E; p = 3.59e-14). These
results indicate that the activation of endogenous OCT4
and SOX2 is correlated with the induction of type III and
ESC/iPSC gene signatures in human. In addition, we found
that whereasMYC and KLF4 are targeted by NANOG only,
OCT4 and SOX2 are co-targeted by NANOG, PRDM14, and
LIN28A (Figure 6D), supporting our hypothesis that co-
regulation of multiple pluripotent transcription factors is
required to regulate type III and iPSC gene signatures.DISCUSSION
Dissecting the transcriptional landscape of reprogramming
represents one of the most straightforward ways to under-
stand cell fate change. Most previous studies performed
gene expression profiling in whole population of cells un-
dergoing reprogramming. Only recently, the Yamanaka
group described the transcriptome changes during human
somatic cell reprogramming by microarray analysis of
TRA160 sorted cells (Tanabe et al., 2013). Here, we used
RNA-Seq to perform extensive transcriptome analyses of
somatic cells undergoing reprogramming based on more
elaborate combinatorial staining with CD13, SSEA4, and
TRA160 and retroviral GFP.1136 Stem Cell Reports j Vol. 4 j 1125–1139 j June 9, 2015 j ª2015 The AutBy analyzing cells 3 days post-reprogramming factor in-
duction, we demonstrated that the earliest gene expression
response is independent of chromatin changes induced by
OSKM. Although a previous study demonstrated that as
pioneer regulators OCT4, SOX2, and KLF4 bind to the
closed chromatin regions and initiate chromatin rearrange-
ments (Soufi et al., 2012), our results showed that genes
located at the closed chromatin regions do not show large
transcriptional differences at day 3. Our observation sug-
gests that 3 days is too short a time to remodel the fibroblast
closed chromatin structure byOSK and that the initial gene
regulation is mainly controlled by OKM transcriptional
regulatory function.
Current transcriptome analysis by RNA-seq identified a
large number of splicing variants of genes expressed at pro-
gressive stages of reprogramming, in addition to parental
fibroblasts and iPSCs. In particular, we found that CCNE1
expresses human-specific pluripotent splicing variant
pCCNE1 only when cells acquire pluripotency. One of the
known functions of CCNE1 involves promoting the entry
of G1 to S phase by binding to phospho-cyclin-dependent
kinase 2 (pCDK2). Overexpression of a full-length uCCNE1
was not effective in promoting reprogramming, while
pCCNE1 improved reprogramming without influencing
cell-cycle progression. These data suggest that pCCNE1
possesses a pluripotency-specific function different from
the cell-cycle-related general function of uCCNE1. The
pCCNE1 isoform lacks exon 9, which is composed of two
a helices and a loop (Figure S3A), and may thus play a
role independently of its interaction with pCDK (Honda
et al., 2005) and its localization at the centrosome (Matsu-
moto and Maller, 2004). In addition to pCCNE1, a large
number of spliced forms of previously uncharacterized
genes were identified in our analysis, and our data will be
a very useful resource to dissect the regulation of gene
splicing during reprogramming and function of genes
uniquely spliced at pluripotency.
We found that the transitions of type I to types II and III
are accompanied by dramatic changes in multiple signal
transduction pathways. Interestingly, the P53 pathway
was enriched in type III to ESC/iPSC in human and Oct4-
GFP+ to iPSCs in mouse. Initially this finding seems some-
what contradictory, as P53 downregulation has been
consistently shown to enhance the reprogramming pro-
cess. However, at least in the human data, we found enrich-
ment of cell-cycle-related genes, stress response, and DNA
repair at later reprogramming stages. Since iPSCs have
somatic mutations independently of derivation method
as well as chromosomal aberrations of parental origin and
from early and late passages (Gore et al., 2011; Johannesson
et al., 2014), upregulation of P53 pathway could be a
response to counter these genetic changes and maintain
DNA integrity. Thus, although the purpose of late P53hors
induction is unclear at present, our data and previous
studies point to one or more combinations of a faster
cell cycle, reprogramming itself, original parental aberra-
tions, and culture conditions. Similarly, we identified the
biphasic repression and induction of the NOTCH signaling
pathway, consistent with a recent report (Ichida et al.,
2014). We further validated that activation of NOTCH
pathway at a late time point increases reprogramming
efficiency. We provide valuable information on the
distinct function of signaling factors during different stages
of reprogramming in order to more efficiently generate
iPSCs.
Overall, our robust transcriptome data in cells undergo-
ing hiPSC reprogramming showed dramatic changes in
cell signaling pathways, human-specific AS, and ASE
during the progressive cell fate change of fibroblasts to
iPSCs (Figure 6E). The data will broaden the knowledge of
the reprogramming process and human-specific gene
regulation.EXPERIMENTAL PROCEDURES
Cell Culture
Normal primary fibroblast Detroit 551 were purchased fromAmer-
ican Type Culture Collection (CCL-110) andmaintained inDMEM
high glucose (GIBCO) supplemented with 10% fetal bovine serum
(FBS) and penicillin/streptomycin. Human ESCs and iPSCs were
cultured on irradiated murine embryonic feeder cells in medium
containing DMEM/F12, 20% knockout serum replacement, and
4 ng/ml basic fibroblast growth factor (bFGF).
iPSC Reprogramming and Cell Sorting
The reprogramming procedure was conducted as previously
described (Park et al., 2008b). Detroit 551 cells were seeded at
100,000 cells/well of a six-well plate 1 day prior to infection.
A retrovirus cocktail containing OSKM was added to each well at
MOI 5. On day 5 post-infection, the cells were trypsinized and
transferred to 10-cm culture dishes containing MEFs. Prior to
sorting, the cells were detached using accutase, washed, and
incubated in 20% FBS in 13 PBS with the following antibodies ac-
cording to manufacturer’s recommended dilutions: anti-human
CD13 (BD catalog number 555394), anti-human/mouse SSEA4
(R&D catalog number FAB1435A), anti-human TRA160 (BD cata-
log number 560193). Sorting was conducted using a BD
FACSAria cell sorter. Then the cells were pelleted and quickly
frozen in liquid nitrogen or sorted directly in RLT + 2-mercaptoe-
thanol lysis buffer (QIAGEN).
PMA RNA-Seq Library Construction and Illumina
Sequencing
PMA RNA-seq library was prepared as previously described (Pan
et al., 2013). Reads mapped to hg19 human genome were used
for subsequent analyses. The details are given in Supplemental
Experimental Procedures. All public data used in this study were
summarized in Table S5.Stem CGene Expression Analysis
RNA was isolated using an RNeasy minikit (QIAGEN) and used for
reverse transcription with iScript (BioRad) according to the manu-
facturer’s protocol with primer sets in Table S6.
ACCESSION NUMBERS
The accession number for the pCCNE1 reported in this paper is
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